172 related articles for article (PubMed ID: 31587551)
1. Effects of Naloxegol on Gastrointestinal Transit and Colonic Fecal Volume in Healthy Participants Receiving Oxycodone.
Olesen AE; Grønlund D; Mark EB; Krogh K; Frøkjær JB; Drewes AM
J Neurogastroenterol Motil; 2019 Oct; 25(4):602-610. PubMed ID: 31587551
[TBL] [Abstract][Full Text] [Related]
2. Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system: Effect of opioids.
Mark EB; Klinge MW; Grønlund D; Poulsen JL; Schlageter V; Scott SM; Krogh K; Drewes AM
Neurogastroenterol Motil; 2020 Mar; 32(3):e13753. PubMed ID: 31721398
[TBL] [Abstract][Full Text] [Related]
3. Effects of naloxegol on whole gut transit in opioid-naïve healthy subjects receiving codeine: A randomized, controlled trial.
Halawi H; Vijayvargiya P; Busciglio I; Oduyebo I; Khemani D; Ryks M; Rhoten D; Burton D; Szarka LA; Acosta A; Camilleri M
Neurogastroenterol Motil; 2018 May; 30(5):e13298. PubMed ID: 29405492
[TBL] [Abstract][Full Text] [Related]
4. The impact of naloxegol on anal sphincter function - Using a human experimental model of opioid-induced bowel dysfunction.
Grønlund D; Poulsen JL; Krogh K; Brock C; Liao D; Gregersen H; Drewes AM; Olesen AE
Eur J Pharm Sci; 2018 May; 117():187-192. PubMed ID: 29432808
[TBL] [Abstract][Full Text] [Related]
5. Tapentadol results in less deterioration of gastrointestinal function and symptoms than standard opioid therapy in healthy male volunteers.
Mark EB; Nedergaard RB; Hansen TM; Nissen TD; Frøkjaer JB; Scott SM; Krogh K; Drewes AM
Neurogastroenterol Motil; 2021 Nov; 33(11):e14131. PubMed ID: 34051122
[TBL] [Abstract][Full Text] [Related]
6. The role of naloxegol in the management of opioid-induced bowel dysfunction.
Leppert W; Woron J
Therap Adv Gastroenterol; 2016 Sep; 9(5):736-46. PubMed ID: 27582887
[TBL] [Abstract][Full Text] [Related]
7. Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350.
Poulsen JL; Mark EB; Brock C; Frøkjær JB; Krogh K; Drewes AM
J Neurogastroenterol Motil; 2018 Jan; 24(1):119-127. PubMed ID: 29291613
[TBL] [Abstract][Full Text] [Related]
8. MRI analysis of fecal volume and dryness: Validation study using an experimental oxycodone-induced constipation model.
Mark EB; Bødker MB; Grønlund D; Østergaard LR; Frøkjaer JB; Drewes AM
J Magn Reson Imaging; 2019 Sep; 50(3):733-745. PubMed ID: 30609164
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Opioid Treatment on Regional Gastrointestinal Transit.
Poulsen JL; Nilsson M; Brock C; Sandberg TH; Krogh K; Drewes AM
J Neurogastroenterol Motil; 2016 Apr; 22(2):282-91. PubMed ID: 26811503
[TBL] [Abstract][Full Text] [Related]
10. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
Webster L; Dhar S; Eldon M; Masuoka L; Lappalainen J; Sostek M
Pain; 2013 Sep; 154(9):1542-1550. PubMed ID: 23726675
[TBL] [Abstract][Full Text] [Related]
11. Naloxegol for opioid-induced constipation in patients with noncancer pain.
Chey WD; Webster L; Sostek M; Lappalainen J; Barker PN; Tack J
N Engl J Med; 2014 Jun; 370(25):2387-96. PubMed ID: 24896818
[TBL] [Abstract][Full Text] [Related]
12. Comparison of subjective and objective measures of constipation - Employing a new method for categorizing gastrointestinal symptoms.
Grønlund D; Vase L; Knudsen SA; Christensen M; Drewes AM; Olesen AE
J Pharmacol Toxicol Methods; 2018; 94(Pt 2):23-28. PubMed ID: 30149126
[TBL] [Abstract][Full Text] [Related]
13. Acute opioid withdrawal syndrome from naloxone/naloxegol interaction.
Olmo M; González-Barboteo J; Moreno D; Coma E; Serrano G
BMJ Support Palliat Care; 2021 Dec; 11(4):408-410. PubMed ID: 32788278
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic Profile of Naloxegol, a Peripherally Acting
Floettmann E; Bui K; Sostek M; Payza K; Eldon M
J Pharmacol Exp Ther; 2017 May; 361(2):280-291. PubMed ID: 28336575
[TBL] [Abstract][Full Text] [Related]
15. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
Corsetti M; Tack J
Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use.
Nalamachu S; Gudin J; Datto C; Coyne K; Poon JL; Hu Y
J Opioid Manag; 2018; 14(3):211-221. PubMed ID: 30044486
[TBL] [Abstract][Full Text] [Related]
17. Although tapentadol and oxycodone both increase colonic volume, tapentadol treatment resulted in softer stools and less constipation: a mechanistic study in healthy volunteers.
Mark EB; Frøkjær JB; Hansen TM; Nedergaard RB; Drewes AM
Scand J Pain; 2021 Apr; 21(2):406-414. PubMed ID: 33606931
[TBL] [Abstract][Full Text] [Related]
18. Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients.
van Malderen K; Halawi H; Camilleri M
Neurogastroenterol Motil; 2018 May; 30(5):e13250. PubMed ID: 29119706
[TBL] [Abstract][Full Text] [Related]
19. A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans.
Jeong ID; Camilleri M; Shin A; Iturrino J; Boldingh A; Busciglio I; Burton D; Ryks M; Rhoten D; Zinsmeister AR
Aliment Pharmacol Ther; 2012 May; 35(9):1088-96. PubMed ID: 22348605
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction.
Leppert W
Drug Des Devel Ther; 2015; 9():2215-31. PubMed ID: 25931815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
